Navigation Links
Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
Date:10/21/2010

ormer Chair of Neuro-Oncology at Memorial Sloan-Kettering Cancer Center commented, "The emerging data from the combination of Xerecept and Avastin is an important development that strongly suggests the need for evaluation of this combination treatment in patients.  Combination therapies are an important part of modern anticancer therapy.  The use of rational combinations of targeted, mechanism-based treatments offers the clinical oncologist the promise of more potent therapeutic options for addressing the multifaceted complexity of cancer."

Celtic Pharma is actively exploring clinical trial strategies to assess combination treatments of Xerecept with Avastin in order to validate these important preclinical findings in a clinical setting, and is also considering the potential for exploring Xerecept in combination with other leading cancer therapies. Celtic Pharma is in productive discussions with the U.S. Food and Drug Administration (FDA) in regards to the design of a registrational study evaluating objectively the clinical benefit associated with reductions in steroid dosing that may be achieved with the use of Xerecept in both primary and metastatic brain tumor patients. Celtic Pharma is also currently evaluating Xerecept in a pediatric trial for patients requiring high doses of corticosteroids to control their cerebral edema, with resulting heavy burdens of steroid-related symptoms.

Preclinical Studies

Several preclinical studies using implanted solid tumor (breast and colon) human xenografts into nude mice, as well as both pediatric and adult human brain tumor xenografts, were evaluated when treated with Xerecept® alone and in combination with Avastin®.  All of these particular models demonstrated statistically significant tumor regression and prolongation of survival following combination treatment with Xerecept and Avastin, compared to Xerecept or Avastin alone.

Specifically, in the human breast model
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
2. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
3. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
4. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
5. Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  Tasly ... way to modernize medicine, announced today the launch ... of nutraceuticals developed to address men and women ... healthy and vibrant into old age while helping ... includes three condition-specific, whole-food and herb-based formulas, namely, ...
(Date:9/30/2014)... Sept. 30, 2014 STUDY OBJECTIVES ... is to provide an overview of the current ... protein drugs/therapeutics. The key objective is to present ... drugs as an important tool in the treatment ... and future strategies within the protein therapeutics market, ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4
... , PITTSBURGH , June 17 Mylan ... Mylan Pharmaceuticals Inc. received final approval from the U.S. Food ... (ANDA) for Hydroxyzine Hydrochloride Tablets 10 mg, 25 mg and ... therefore, therapeutically equivalent to Pliva,s Hydroxyzine Hydrochloride Tablets, a treatment ...
... Copan unveiled new groundbreaking features of its Walk-Away Specimen ... American Society for Microbiology (ASM) in San Diego, California ... to the market in 2008 with the launch of the ... all microbiology samples. While attending the 110th ASM meeting, Copan ...
Cached Medicine Technology:Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets 2Copan Redefines Automated Specimen Processing with Groundbreaking New Features 2Copan Redefines Automated Specimen Processing with Groundbreaking New Features 3
(Date:10/2/2014)... By Dennis Thompson ... -- Forty-two states and the District of Columbia now have ... severe respiratory illness that has been infecting children since ... infected with the virus have died in recent weeks, but ... virus played in those deaths, officials said. Health officials ...
(Date:10/1/2014)... Journal of the American Medical Association shows ... or severe chronic knee pain, acupuncture did not provide ... randomly assigned 282 patients (50 years or older) with ... pretend laser treatment. , Treatments were delivered for ... and sham (inactive) laser acupuncture. , Researcher Professor Kim ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... LOUIS, MO (PRWEB) October 01, 2014 Join ... for Castlewood Eating Disorder Treatment Center’s first ever charity golf ... grants for people with eating disorders who cannot afford treatment. ... Run Golf Club in Eureka, Mo. , The day-long ... at noon. A reception and award dinner will begin at ...
Breaking Medicine News(10 mins):Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... -- About one-fourth of all black men and women carry ... artery disease, new research reveals. The mutation is found ... higher risk for heart disease among other races, the ... and women who carry this single variation, the risk for ...
... College of Medicine and Dentistry (PCMD), University of Exeter, is ... form a 6m research and analysis network, funded by the ... the possible role of virus infection in the cause of ... lead to the development of a vaccine to prevent diabetes ...
... Injury Research and Policy of The Research Institute at ... adolescents 6 to 18 years old and found that ... departments from 1994 through 2007, for an average of ... study period, the annual number of running-related injuries increased ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Work-related ... has found. Israeli researchers gave hearing tests to 298 ... harmful noise and found that 99 of the workers had ... hearing problems tended to be older and to have been ...
... Illinois study provides convincing evidence that the way you ... that teaming broccoli with broccoli sprouts may make the ... prepared correctly, is an extremely potent cancer-fighting agentthree to ... effect. To get broccoli,s benefits, though, the enzyme myrosinase ...
... of psychological resources, such as commitment and a sense of ... lead to loss of resources and other negative affects. This ... of Haifa. "Mass media plays a central role in reporting ... watching this type of coverage on television has negative effects, ...
Cached Medicine News:Health News:Gene Mutation May Protect Blacks From Heart Disease 2Health News:6 million euros for European Diabetes Research Network 2Health News:Sprouts? Supplements? Team them up to boost broccoli's cancer-fighting power 2Health News:Watching TV coverage of terror makes viewers feel threatened 2
Suture Cutters, Straight...
Suture scissor...
Threaded cannula for use with Suretac® II, sterile packs, box of 10....
The Small Oval Cannula System is designed to be the smallest oval cannula system currently available, and is utilized with the Caspari Suture Punch System. Disposable seals are available with this sy...
Medicine Products: